Dexamethasone and the Prevention of Post-Extubation Airway Obstruction in Adults

NCT ID: NCT00452062

Last Updated: 2007-03-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

70 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-10-31

Study Completion Date

2007-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Laryngotracheal injury related to intubation may cause narrowing of the airway due to edema of the glottis. Post-extubation airway frequently necessitating re-intubation and resulting in the prolongation of intensive care. Factors correlating with the development of post-extubation stridor include age, female gender, an elevated Acute Physiologic and Chronic Health Evaluation II, trauma related to endotracheal intubation, excessive ETT size, unnecessary tube mobility, increased cuff pressure, frequent tracheal aspirations, infection, arterial hypotension, and a prolonged intubation period. Because the presence of an endotracheal tube (ETT) precludes direct visualization of the upper airway, recognition of edema due to laryngotracheal injury is often difficult. However, upper airway patency may be measured indirectly in the intubated patient by documentation of a leak around the ETT upon deflation of the sealing balloon cuff encircling the ETT. Controversy currently exists regarding the effectiveness of prophylactic steroid therapy for patients considered at high risk for post-extubation stridor. Only a limited number of prospective trials involving adults and evaluating the benefits of corticosteroid therapy prior to extubation have been conducted.

Studies regarding the efficacy of prophylactic corticosteroids for intubated patients have yielded conflicting results due to differences in the number of doses or types of corticosteroids administered.

The present study was conducted to evaluate the effects of prophylactic dexamethasone therapy for a subset of high-risk patients who had been intubated for \> 48 hours and who were undergoing their first elective extubation in an ICU setting. The specific objectives were to determine whether multiple doses of dexamethasone are effective in the reduction or prevention of post-extubation airway obstruction in patients with a cuff leak volume (CLV) \< 110 mL and to ascertain whether an aftereffect follows the discontinuation of dexamethasone.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Materials and methods Patients The current study included patients admitted to the adult medical ICU of the Mackay Memorial Medical Center from 1 October 2004 and 1 July 2007 and who met the inclusion criteria described below. Informed consent was obtained from the patients or their relatives prior to entering the trial. This study was approved by the Institutional Research Ethics Board. The cuff-leak test was therefore administered to patients requiring mechanical ventilation for more than 48 hours. All patients were \> 18 years of age and met the following weaning criteria: 1) temperature ≤ 38°C for \> 8 hours, 2) discontinuous use of sedatives, 3) heart rate ≥ 70 and ≤ 130 /min, 4) systolic blood pressure (SBP) ≥ 80 mm Hg in the absence of vasopressors, 5) fraction of inspired oxygen (FiO2) ≤ 0.6, PaO2 ≥ 60, and partial pressure of oxygen (PaO2)/FiO2 ratio \> 200, 6) positive end-expiratory pressure (PEEP) ≤ 5 cm H2O, 7) rapid and shallow ratio of frequency to tidal volume (f/VT ≤ 105), 8) minute ventilation ≤ 15 L/min, and 9) pH ≥ 7.3. Supplemental oxygen was continued to maintain an oxygen saturation \> 95% as measured by a pulse oximeter.

Exclusion criteria were: 1) the need for more than one tracheal intubation during the hospital stay, 2) unstable hemodynamics (i.e., a mean SBP \< 90 mm Hg, a SBP decrease \> 40 mm Hg, or a mean arterial pressure \[MAP\] \< 70 mm Hg), 3) profound recalcitrant hypoxemia (i.e., PaO2 \< 60 mm Hg with a FiO2 \> 0.50), or 4) administration of corticosteroids 7 days prior to extubation. All patients were intubated with a high-volume, low-pressure cuffed ETT. Patients exhibiting excessive movement were sedated or paralyzed during mechanical ventilation. Routine nursing care included ETT suctioning every 2 hours or as needed to maintain a patent airway. Patients were mechanically ventilated in the volume-assisted control mode with a tidal volume of 10 mL/kg of ideal body weight, a respiratory rate of 20 breaths/minute, and a zero PEEP during CLV measurement. The operator-selected inspiratory tidal volume of 10 mL per kilogram of ideal body weight, displayed as an expiratory tidal volume, was recorded. The balloon cuff was deflated, the expiratory tidal volume was recorded over the 6 subsequent respiratory cycles, and the average of the lowest 3 values was utilized for subsequent analyses. The CLV was determined as the difference in the actual tidal volume before and after cuff deflation.

Study protocol Patients requiring mechanical ventilation for \> 48 hours and exhibiting a CLV \< 110 mL were therefore included in the trial. The study was prospective, randomized, double-blind, and placebo-controlled. The randomization procedure was performed by a respiratory therapist not involved in patient care using blocked randomization. Patients were randomized to receive intravenous dexamethasone 5 mg per injection, or intravenous normal saline at an equivalent volume. Dexamethasone or normal saline (placebo) was administered every 6 hours for a total of 4 doses. Cuff leak tests were measured one hour after each injection and 24 hours after the 4th injection of dexamethasone or placebo. Both the physician and the staff who administered the treatment were blinded. The ICU physicians were not apprised of the measurements obtained by the respiratory therapist. Extubation was carried out 24 hours after the last injection of intervention fluid. After extubation, the presence of an audible, high-pitched wheeze was an indication for the inhalation of racemic epinephrine.

Patients meeting at least two of the following criteria were assigned to take non-invasive positive-pressure ventilation by face mask: 1) respiratory acidosis (defined as an arterial pH \< 7.35 with a partial pressure of arterial carbon dioxide \> 45 mm Hg), 2) clinical signs suggestive of respiratory-muscle fatigue or increased respiratory effort (i.e., use of accessory muscles, intercostal retraction, or paradoxical motion of the abdomen), 3) a respiratory rate \> 25 breaths per minute for 2 consecutive hours, and 4) hypoxemia (defined as an arterial oxygen saturation of \< 90 % or a PaO2 of \< 80 mm Hg with a FiO2 \> 0.50). Patients were re-intubated with mechanical ventilation support if they met at least one of the following criteria: 1) pH \< 7.3 with a partial pressure of carbon dioxide increase \> 15 mm Hg, 2) a change in mental status rendering the patient unable to tolerate non-invasive ventilation, 3) a decrease in the oxygen saturation to \< 85% despite the use of a high fraction of inspired oxygen (a PaO2 \< 50 mm Hg with a FiO2 \> 70 %), 4) lack of improvement in signs of respiratory-muscle fatigue, 5) hypotension with a SBP \< 80 mm Hg for more than 30 minutes despite adequate volume challenge, 6) a diastolic blood pressure drop \> 20 mm Hg, and 7) copious secretions that could not be adequately cleared or that were associated with acidosis, hypoxemia, or changes in mental status (somnolence, agitation, or diaphoresis).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Airway Obstruction

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

cuff-leak test intubation corticosteroids dexamethasone to reduce the occurrence of post-extubation airway obstruction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dexamethasone

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

All patients were \> 18 years of age and met the following weaning criteria:

1. Temperature ≤ 38°C for \> 8 hours,
2. Discontinuous use of sedatives,
3. Heart rate ≥ 70 and ≤ 130 /min,
4. Systolic blood pressure (SBP) ≥ 80 mm Hg in the absence of vasopressors,
5. Fraction of inspired oxygen (FiO2) ≤ 0.6, PaO2 ≥ 60, and partial pressure of oxygen (PaO2)/FiO2 ratio \> 200,
6. Positive end-expiratory pressure (PEEP) ≤ 5 cm H2O,
7. Rapid and shallow ratio of frequency to tidal volume (f/VT ≤ 105),
8. Minute ventilation ≤ 15 L/min, and
9. pH ≥ 7.3. Supplemental oxygen was continued to maintain an oxygen saturation \> 95% as measured by a pulse oximeter.

Exclusion Criteria

1. The need for more than one tracheal intubation during the hospital stay,
2. Unstable hemodynamics (i.e., a mean SBP \< 90 mm Hg, a SBP decrease \> 40 mm Hg, or a mean arterial pressure \[MAP\] \< 70 mm Hg),
3. Profound recalcitrant hypoxemia (i.e., PaO2 \< 60 mm Hg with a FiO2 \> 0.50), or
4. Administration of corticosteroids 7 days prior to extubation.
Minimum Eligible Age

18 Years

Maximum Eligible Age

95 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Mackay Memorial Hospital

OTHER

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Chao-Hsien Lee, MD

Role: PRINCIPAL_INVESTIGATOR

Mackay Memorial Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Mackay Memorial Hospital

Taipei, Taipei, Taiwan

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Taiwan

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Chao-Hsien Lee, MD

Role: CONTACT

Phone: +886-2-23926589

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Wan-Ting Chen, Ms

Role: primary

References

Explore related publications, articles, or registry entries linked to this study.

Cheng KC, Hou CC, Huang HC, Lin SC, Zhang H. Intravenous injection of methylprednisolone reduces the incidence of postextubation stridor in intensive care unit patients. Crit Care Med. 2006 May;34(5):1345-50. doi: 10.1097/01.CCM.0000214678.92134.BD.

Reference Type RESULT
PMID: 16540947 (View on PubMed)

Anene O, Meert KL, Uy H, Simpson P, Sarnaik AP. Dexamethasone for the prevention of postextubation airway obstruction: a prospective, randomized, double-blind, placebo-controlled trial. Crit Care Med. 1996 Oct;24(10):1666-9. doi: 10.1097/00003246-199610000-00011.

Reference Type RESULT
PMID: 8874303 (View on PubMed)

Chung YH, Chao TY, Chiu CT, Lin MC. The cuff-leak test is a simple tool to verify severe laryngeal edema in patients undergoing long-term mechanical ventilation. Crit Care Med. 2006 Feb;34(2):409-14. doi: 10.1097/01.ccm.0000198105.65413.85.

Reference Type RESULT
PMID: 16424722 (View on PubMed)

Lee CH, Peng MJ, Wu CL. Dexamethasone to prevent postextubation airway obstruction in adults: a prospective, randomized, double-blind, placebo-controlled study. Crit Care. 2007;11(4):R72. doi: 10.1186/cc5957.

Reference Type DERIVED
PMID: 17605780 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MMH-I-S-106

Identifier Type: -

Identifier Source: org_study_id